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Background
Monoamine transporters such as the dopamine trans-
porter (DAT) and the serotonin transporter (SERT)
mediate the reuptake of previously released monoamines
dopamine (DA) and serotonin from the synaptic cleft;
thereby, these transporters regulate the monoamine con-
tent available for synaptic transmission. Certain stimuli,
such as changes in ionic composition of the extracellular
fluid or psychostimulants (e.g. amphetamines) are able
to induce outward transport and thus increase extracel-
lular monoamine concentrations. Influx and efflux of
substrate are thought to be asymmetrical processes
regulated by intracellular kinases. It has been demon-
strated that removal of N-terminal serines ablates
amphetamine-induced reverse transport in the DAT.
Furthermore, the Ca2+/calmodulin-dependent protein
kinase II a (aCaMKII) can bind to the DAT C-terminus
and phosphorylate N-terminal serines. Pharmacological
inhibition of aCaMKII dramatically reduces ampheta-
mine-induced efflux both in cells stably transfected with
the human DAT as well as in rat striatal slices. Here, we
test whether aCaMKII-regulation of amphetamine-
induced reverse transport of monoamines is affected in
mice with mutations in the aCaMKII gene.
Methods
Methods used were: release assays in mouse brain pre-
parations, radioligand binding and uptake experiments,
immunoprecipitations, surface biotinylation, mass
spectrometry, primary cultures of dopaminergic and ser-
otonergic neurons, immunocytochemistry and beha-
vioural pharmacology.
Results
We show here that aCaMKII regulates amphetamine-
induced DAT-mediated efflux in mice with various
mutations in the aCaMKII gene. Mice lacking aCaMKII
or having a permanently self-inhibited aCaMKII (aCaM-
KIIT305D) display significantly reduced amphetamine-
induced substrate efflux. A similar finding was observed
in a mouse model of Angelman Syndrome, a neuroge-
netic disease characterized by motor impairments and
autism spectrum disorders. Angelman Syndrome mice
have a reduced aCaMKII activity and show comparable
impairments in DAT function to aCaMKII mutants.
This suggests that DAT-mediated dopaminergic signal-
ling is affected in Angelman Syndrome. We further
show that aCaMKII regulates the closely related SERT:
both pharmacological inhibition and genetic disruption
of aCaMKII significantly attenuates p-chloro-ampheta-
mine-induced SERT-mediated serotonin efflux in transi-
ently transfected cells and mouse brain preparations.
Conclusions
aCaMKII exerts an important modulatory role in amphe-
tamine-induced DAT- and SERT-mediated substrate
efflux. The finding that efflux is also affected in Angel-
man Syndrome mice might help in the understanding of
the underlying pathophysiology. Symptoms of human
Angelman Syndrome patients include movement impair-
ments and autism spectrum disorders, conditions which
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are associated with dopaminergic and serotonergic
malfunction.
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